STOCK TITAN

Gilead to acquire Arcellx (ACLX) with $115 cash plus $5 CVR offer

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Arcellx, Inc. is set to be acquired under a tender offer backed by a major shareholder group led by New Enterprise Associates. Gilead Sciences, through a subsidiary, agreed to launch an offer for all Arcellx common shares at $115.00 in cash per share plus one contingent value right (CVR) that may pay an additional $5.00 in cash if a specified milestone is achieved.

Following completion of the offer, Arcellx will merge with the Gilead subsidiary, with Arcellx surviving. NEA 15 holds 3,045,262 Arcellx shares, representing 5.3% of the common stock based on 57,822,871 shares outstanding as of October 31, 2025. NEA 15 and certain other stockholders entered into support agreements committing to tender their shares and vote in favor of the merger, while generally opposing competing acquisition proposals.

Positive

  • None.

Negative

  • None.

Insights

Large Arcellx holder commits its 5.3% stake to Gilead’s cash-and-CVR takeover.

The filing shows NEA 15 and affiliated entities owning 3,045,262 Arcellx shares, or 5.3% of the company based on 57,822,871 shares outstanding as of October 31, 2025. They have entered into tender and support agreements connected to Gilead’s acquisition of Arcellx.

Gilead’s subsidiary will launch a tender offer at $115.00 in cash per share plus a CVR that can pay $5.00 in cash upon achieving a defined milestone. After the offer is completed, a merger will combine the subsidiary into Arcellx, which will remain as the surviving corporation.

The support agreements require NEA 15 and other specified stockholders to tender all of their shares, vote against alternative acquisition proposals, and support the merger, subject to specified termination events including termination of the merger agreement. Actual closing and any CVR payment depend on the tender offer’s completion, merger conditions, and achievement of the milestone defined in the CVR agreement.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


New Enterprise Associates 15, L.P.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:02/24/2026
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:02/24/2026
NEA Partners 15, L.P.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:02/24/2026
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:02/24/2026
NEA 15 GP, LLC
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:02/24/2026
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:02/24/2026
Forest Baskett
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Forest Baskett
Date:02/24/2026
Anthony A. Florence, Jr.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr.
Date:02/24/2026
Mohamad H. Makhzoumi
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi
Date:02/24/2026
Scott D. Sandell
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Scott D. Sandell
Date:02/24/2026
Comments accompanying signature:
This Amendment No. 5 to Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.

FAQ

What transaction involving Arcellx (ACLX) and Gilead is described here?

Gilead Sciences, through a wholly owned subsidiary, agreed to acquire all Arcellx common shares via a tender offer, followed by a merger where Arcellx survives. The offer combines a fixed cash payment per share with an additional contingent value right.

What are Arcellx shareholders offered per share in the Gilead deal?

Arcellx shareholders are offered $115.00 in cash per share, plus one contingent value right (CVR) per share. Each CVR may pay an additional $5.00 in cash if a specified milestone is achieved under a future contingent value rights agreement.

How many Arcellx shares does NEA 15 beneficially own under this filing?

NEA 15 is the record owner of 3,045,262 Arcellx common shares. This stake is also attributed beneficially to NEA Partners 15, NEA 15 GP, LLC, and the named managers, subject to their disclaimers of beneficial ownership beyond shares held of record.

What percentage of Arcellx does the NEA reporting group hold?

Each reporting person lists beneficial ownership of 5.3% of Arcellx’s common stock. This percentage is calculated using 57,822,871 shares outstanding as of October 31, 2025, as disclosed in Arcellx’s Form 10-Q filed on November 5, 2025.

What obligations do NEA 15 and other stockholders have under the support agreements?

Under the support agreements, each stockholder agrees to tender all of its Arcellx shares, vote against competing acquisition proposals, and vote for proposals related to the merger, subject to specified conditions. These agreements automatically terminate upon certain events, including termination of the merger agreement.

Does this filing indicate recent trading in Arcellx shares by the NEA group?

The filing states that, except as described in the merger-related arrangements, none of the reporting persons has effected any transaction in the NEA 15 shares during the last 60 days. Their current interest primarily reflects the existing 3,045,262-share position and associated support commitments.